Minims Cyclopentolathydrochlorid Bausch + Lomb Ireland Limited (Cyclopentolate Hydrochloride)

Cyclopentolate blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary body. By preventing parasympathetic signaling, it stops the muscles that constrict the pupil and focus the lens, leading to a widened pupil and loss of accommodation, which are useful for diagnostic and therapeutic purposes.

The dosing regimen for Minims Cyclopentolathydrochlorid is determined by the prescribing ophthalmologist based on the specific clinical need, patient age, and response. The product is supplied as eye drops, and the prescriber will specify the number of drops and frequency.

Safety data for cyclopentolate in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Cyclopentolate provides both mydriasis and cycloplegia, unlike agents such as tropicamide which mainly cause dilation with limited cycloplegic effect. Compared with phenylephrine, cyclopentolate works via antimuscarinic mechanisms rather than adrenergic stimulation, offering a different side‑effect profile and duration of action.

The eye drops should be stored at room temperature, ideally below 25 °C, in the original container. Protect the product from direct light and moisture, and keep the cap tightly closed when not in use to maintain stability.

The medication is applied topically to the eye. The prescriber will instruct the patient to instill the specified number of drops into the conjunctival sac, usually one or two drops per eye, and to keep the eyes closed briefly to enhance absorption.

Serious risks include acute angle‑closure glaucoma, severe allergic reactions such as contact dermatitis, and rare systemic anticholinergic toxicity. Patients should be monitored for signs of increased intra‑ocular pressure, severe eye pain, or systemic symptoms like confusion or rapid heartbeat.

Patients with known hypersensitivity to cyclopentolate or any formulation components, those with narrow‑angle or uncontrolled glaucoma, and individuals in whom the risks of anticholinergic effects outweigh the benefits should avoid using this product. The prescriber will assess suitability on a case‑by‑case basis.